Targeted Oncology

, Volume 2, Issue 4, pp 253–257

Effect of cetuximab in recurrent and refractory squamous cell carcinoma of the head and neck (SCCHN): a case report

  • Clorinda Schettino
  • Maria Anna Bareschino
  • Katia Monaco
  • Michele Orditura
  • Ferdinando De Vita
  • Fortunato Ciardiello
Day-to-Day Practice

DOI: 10.1007/s11523-007-0061-6

Cite this article as:
Schettino, C., Bareschino, M.A., Monaco, K. et al. Targ Oncol (2007) 2: 253. doi:10.1007/s11523-007-0061-6
  • 44 Downloads

Abstract

The epidermal growth factor receptor (EGFR) is frequently overexpressed in squamous cell carcinoma of head and neck (SCCHN). Different strategies to target the activated EGFR have reached the clinic. Cetuximab is a monoclonal antibody that selectively binds to the extracellular domain of the EGFR on the tumor cell, thereby inhibiting receptor-associated tyrosine kinase activation. Two randomized phase III clinical trials have recently demonstrated that cetuximab increases the activity of radiotherapy in the treatment of locally advanced SCCHN and of platinum-based chemotherapy in the treatment of metastatic SCCHN. Here we report the clinical case of a long-lasting complete response in a 57-year-old male, who was a current smoker and had a history of alcohol abuse, affected by recurrent locally advanced SCCHN after failure of radiotherapy and of platinum-based chemotherapy.

Keywords

Head and neck cancerCetuximabMonoclonal antibodies (MAbs)Epidermal growth factor receptor (EGFR)Antitumor activityCase report

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Clorinda Schettino
    • 1
  • Maria Anna Bareschino
    • 1
  • Katia Monaco
    • 1
  • Michele Orditura
    • 1
  • Ferdinando De Vita
    • 1
  • Fortunato Ciardiello
    • 1
  1. 1.Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F. Magrassi and A. LanzaraSecond University of Naples School of MedicineNaplesItaly